This Article Figures Only Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alfonso, F. Search for Related Content PubMed PubMed Citation Articles by Alfonso, F. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis

Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial

Fernando Alfonso, MD^_*,_*, Maria-José Pérez-Vizcayno, MD^_*, Rosana Hernandez, MD^_*, Armando Bethencourt, MD, Vicens Martí, MD, Jose R. López-Mínguez, MD, Juan Angel, MD^||, Ramón Mantilla, MD^¶, Cesar Morís, MD^#, Angel Cequier, MD^_**, Manel Sabaté, MD^_*, Javier Escaned, MD^_*, Raúl Moreno, MD^_*, Camino Bañuelos, MD^_*, Alfonso Suárez, MD^_*, Carlos Macaya, MD^_* for the RIBS-II Investigators

^_* Clinico San Carlos University Hospital, Madrid, Spain
Son Dureta University Hospital, Palma de Mallorca, Spain
San Pablo University Hospital, Barcelona, Spain
Infanta Cristina University Hospital, Badajoz, Spain
^|| Valle de Hebrón University Hospital, Barcelona, Spain
^¶ Meixoeiro University Hospital, Vigo, Spain
^# Central Asturias University Hospital, Oviedo, Spain
^_** Bellvitge University Hospital, Barcelona, Spain

Manuscript received August 21, 2005; revised manuscript received October 14, 2005, accepted October 25, 2005.

^_* Reprint requests and correspondence: Dr. Fernando Alfonso, Cardiología Intervencionista, Instituto Cardiovascular, Hospital Universitario "San Carlos," Ciudad Universitaria, Plaza de Cristo Rey, Madrid 28040, Spain. (Email: falf{at}hotmail.com).

OBJECTIVES: We sought to assess the effectiveness of sirolimus-eluting stents (SES) in patients with in-stent restenosis (ISR).

BACKGROUND: Treatment of patients with ISR remains a challenge.

METHODS: The Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) study is a multicenter randomized trial conducted in 150 patients with ISR (76 allocated to SES and 74 to balloon angioplasty [BA]). The primary end point was recurrent restenosis rate at nine months. Secondary end points included prespecified subgroup analysis, lumen volume on intravascular ultrasound (IVUS), and a composite of major clinical events at one year.

RESULTS: Angiographic success was obtained in all patients. At 9-month angiographic follow-up (96% of eligible patients) minimal lumen diameter was larger (2.52 mm [interquartile range (IQR) 2.09 to 2.81] vs. 1.54 mm [IQR 0.91 to 2.05]; p < 0.001) and recurrent restenosis rate was lower (11% vs. 39%; p < 0.001) in the SES group. Prespecified subgroup analyses were consistent with the main outcome measure. Lumen volume on IVUS at 9 months was also larger (279 mm³ [IQR 227 to 300] vs. 197 mm³ [IQR 177 to 230]; p < 0.001) in the SES group. At one-year clinical follow-up (100% of patients), the event-free survival (freedom from death, myocardial infarction, and target vessel revascularization) was significantly improved in the SES group (88% vs. 69%; p < 0.004) as the result of a lower requirement for target vessel revascularization (11% vs. 30%; p < 0.003).

CONCLUSIONS: In patients with ISR, the use of SES provides superior long-term clinical, angiographic, and IVUS outcome than BA treatment.

Abbreviations and Acronyms   BA = balloon angioplasty   IQR = interquartile range   ISR = in-stent restenosis   IVUS = intravascular ultrasound   PCI = percutaneous coronary interventions   RIBS-II = Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting study   SES = sirolimus-eluting stents

Related Article

Treatment of Stent Restenosis: Moving Beyond Momentum

Harold L. Dauerman
J. Am. Coll. Cardiol. 2006 47: 2161-2163. [Full Text] [PDF]

This article has been cited by other articles:

				F. Alfonso, J. Dutary, M. Paulo, and M. J. Perez-Vizcayno Paclitaxel-Eluting Balloons for Sirolimus-Eluting Stent Restenosis J. Am. Coll. Cardiol. Intv., June 1, 2011; 4(6): 716 - 716. [Full Text] [PDF]

				G. D. Dangas, B. E. Claessen, A. Caixeta, E. A. Sanidas, G. S. Mintz, and R. Mehran In-Stent Restenosis in the Drug-Eluting Stent Era J. Am. Coll. Cardiol., November 30, 2010; 56(23): 1897 - 1907. [Abstract] [Full Text] [PDF]

				S. Garg and P. W. Serruys Coronary Stents: Current Status J. Am. Coll. Cardiol., August 31, 2010; 56(10_Suppl_S): S1 - S42. [Abstract] [Full Text] [PDF]

				P. S. Teirstein Drug-Eluting Stent Restenosis: An Uncommon Yet Pervasive Problem Circulation, July 6, 2010; 122(1): 5 - 7. [Full Text] [PDF]

				M. Abe, T. Kimura, T. Morimoto, T. Taniguchi, F. Yamanaka, K. Nakao, N. Yagi, N. Kokubu, Y. Kasahara, Y. Kataoka, et al. Sirolimus-Eluting Stent Versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry Circulation, July 6, 2010; 122(1): 42 - 51. [Abstract] [Full Text] [PDF]

				F. Alfonso Treatment of Drug-Eluting Stent Restenosis: The New Pilgrimage: Quo Vadis? J. Am. Coll. Cardiol., June 15, 2010; 55(24): 2717 - 2720. [Full Text] [PDF]

				J. Mehilli, R. A. Byrne, K. Tiroch, S. Pinieck, S. Schulz, S. Kufner, S. Massberg, K.-L. Laugwitz, A. Schomig, A. Kastrati, et al. Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study J. Am. Coll. Cardiol., June 15, 2010; 55(24): 2710 - 2716. [Abstract] [Full Text] [PDF]

				F. Liistro, M. Fineschi, S. Grotti, P. Angioli, A. Carrera, K. Ducci, T. Gori, G. Falsini, C. Pierli, and L. Bolognese Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis: Results of the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry at 4 Years J. Am. Coll. Cardiol., February 16, 2010; 55(7): 613 - 616. [Abstract] [Full Text] [PDF]

				A. Caixeta, P. Genereux, G. Dangas, and R. Mehran Chapter 28 In-stent restenosis in the drug-eluting stent era Oxford Textbook of Interventional Cardiology, January 1, 2010; 1(1): med-9780199569083-chapter - med-9780199569083-chapter. [Abstract] [Full Text]

				S. Kufner, J. Hausleiter, G. Ndrepepa, S. Schulz, O. Bruskina, R. A. Byrne, M. Fusaro, A. Kastrati, A. Schomig, J. Mehilli, et al. Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1142 - 1148. [Abstract] [Full Text] [PDF]

				F. Alfonso, J. Garcia, M.-J. Perez-Vizcayno, L. Hernando, R. Hernandez, J. Escaned, P. Jimenez-Quevedo, C. Banuelos, and C. Macaya New Stent Implantation for Recurrences After Stenting for In-Stent Restenosis: Implications of a Third Metal Layer in Human Coronary Arteries J. Am. Coll. Cardiol., September 8, 2009; 54(11): 1036 - 1038. [Full Text] [PDF]

				F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, A. Iniguez, C. Moris, A. Cequier, et al. Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1621 - 1627. [Abstract] [Full Text] [PDF]

				S Habara, K Mitsudo, T Goto, K Kadota, S Fujii, H Yamamoto, H Kato, S Takenaka, Y Fuku, S Hosogi, et al. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis Heart, September 1, 2008; 94(9): 1162 - 1165. [Abstract] [Full Text] [PDF]

				P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1844 - 1853. [Abstract] [Full Text] [PDF]

				K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention J. Am. Coll. Cardiol., February 19, 2008; 51(7): 701 - 707. [Abstract] [Full Text] [PDF]

				C. L. Grines Off-Label Use of Drug-Eluting Stents: Putting it in Perspective J. Am. Coll. Cardiol., February 12, 2008; 51(6): 615 - 617. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]

				H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET) Eur. Heart J., March 2, 2007; 28(6): 719 - 725. [Abstract] [Full Text] [PDF]

				A. Dibra, A. Kastrati, F. Alfonso, M. Seyfarth, M.-J. Perez-Vizcayno, J. Mehilli, and A. Schomig Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials J. Am. Coll. Cardiol., February 6, 2007; 49(5): 616 - 623. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al. Highlights of the Year in JACC 2006 J. Am. Coll. Cardiol., January 30, 2007; 49(4): 509 - 527. [Full Text] [PDF]

				H. L. Dauerman Treatment of Stent Restenosis: Moving Beyond Momentum J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2161 - 2163. [Full Text] [PDF]